Details of the Drug

General Information of Drug (ID: DMD709J)

Drug Name
RM-131
Synonyms Relamorelin
Indication
Disease Entry ICD 11 Status REF
Gastroparesis DA41.00 Phase 3 [1]
Cachexia MG20 Phase 2 [2]
Diabetic gastroparesis DA41.00 Phase 2 [3]
Structure
3D MOL is unavailable 2D MOL
Chemical Identifiers
Formula
C43H50N8O5S
Canonical SMILES
C1CC(CNC1)C(=O)NC(CC2=CSC3=CC=CC=C32)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N
InChI
1S/C43H50N8O5S/c44-42(56)43(16-19-45-20-17-43)51-41(55)34(21-27-9-2-1-3-10-27)49-39(53)35(22-29-25-47-33-14-6-4-12-31(29)33)50-40(54)36(48-38(52)28-11-8-18-46-24-28)23-30-26-57-37-15-7-5-13-32(30)37/h1-7,9-10,12-15,25-26,28,34-36,45-47H,8,11,16-24H2,(H2,44,56)(H,48,52)(H,49,53)(H,50,54)(H,51,55)/t28?,34-,35+,36+/m0/s1
InChIKey
IPMQOGDSJZQLFX-BIBZJUPHSA-N
Cross-matching ID
PubChem CID
85364156
CAS Number
661472-41-9
TTD ID
D0U2CE
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT03426345) Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02357420) A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)